Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07242105 · ClinicalTrials.gov registry record · NA

Optimizing Brain Excitability in Depression

A NA study of Major Depressive Disorder, sponsored by Stanford University.

Recruiting
Registry status
NA
Development phase
145
Enrollment target
2
Study locations

NCT07242105 is a NA study of Major Depressive Disorder that is actively recruiting participants, run by Stanford University. The registered enrollment target is 145 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (61% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07242105, a NA study of Major Depressive Disorder, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
NA
Development phase
145 participants
Enrollment target
2
Study locations

Study Summary

The goal of this study is to improve depression treatment by establishing reliable prefrontal excitability markers through Targeting with Automated Real-time Guidance for Enhancing TEPs (TARGET).

Conditions Studied

Interventions

  • DEVICE Active Single-Pulse TMS
  • DEVICE Sham Single-Pulse TMS
  • DEVICE TARGET-optimized TMS
  • DEVICE Non-optimized (Open-Loop) TMS
  • OTHER EEG Recording

Study Locations (2)

California

  • University of Iowa - Iowa City
  • Stanford University - Stanford

Trial Details

FieldValue
Enrollment Target 145 participants
Start Date 2025-10-23
Est. Completion 2029-11-30
Phase NA

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT07242105

The ClinicalTrials.gov registry entry for NCT07242105 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (61% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 5 interventions - of which Active Single-Pulse TMS is the first listed.

NCT07242105 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT07242105 about?

NCT07242105 is a clinical study titled "Optimizing Brain Excitability in Depression". The goal of this study is to improve depression treatment by establishing reliable prefrontal excitability markers through Targeting with Automated Real-time Guidance for Enhancing TEPs (TARGET).

What is the current status of trial NCT07242105?

This trial is currently recruiting. It is a NA study. The enrollment target is 145 participants. The study started on 2025-10-23. Estimated completion is 2029-11-30.

What conditions does trial NCT07242105 study?

This clinical trial studies the following conditions: Major Depressive Disorder.

What interventions are being tested in trial NCT07242105?

The interventions under investigation include: Active Single-Pulse TMS (DEVICE), Sham Single-Pulse TMS (DEVICE), TARGET-optimized TMS (DEVICE), Non-optimized (Open-Loop) TMS (DEVICE), EEG Recording (OTHER).

Who is sponsoring clinical trial NCT07242105?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07242105 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.